<DOC>
	<DOCNO>NCT02108366</DOCNO>
	<brief_summary>Each year , influenza A infection cause great mortality morbidity , especially among elderly individual chronic illness . Many patient 'late presenter ' admit hospital day symptoms onset developed complication secondary immunodysregulation . Antiviral treatment neuraminidase inhibitor limited usage patient present hospital 48 hour symptom onset . Apart ventilatory extracorporeal membrane oxygenation support , treatment option patient limited . Recent animal study demonstrate combination antiviral agent COX-II inhibitor reduce mortality mouse infect influenza virus . The investigator therefore propose enrol patient severe influenza A infection require hospitalization oxygen support randomize control trial celecoxib .</brief_summary>
	<brief_title>Treatment Severe Influenza A Infection</brief_title>
	<detailed_description>The aim double blind randomize control trial compare clinical efficacy safety celecoxib combine neuraminidase inhibitor patient severe influenza A infection . The hypothesis study treatment severe influenza A infection celecoxib reduce mortality . The primary outcome assess 28-days mortality rate hospitalization . The secondary outcome assess safety treatment , duration intensive care , duration ventilatory oxygen support , viral load cytokine change .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 ) Male female patient â‰¥18 year 2 ) Written informed consent patient nextof kin ( patient ill consent ) 3 ) Presumptive diagnosis influenza A satisfying clinical laboratory criterion . The laboratory criterion define least one RTPCR positive influenza A ( H1N1 , H3N2 , H5N1 H7N9 ) respiratory clinical specimen include nasopharyngeal sample endotracheal aspirate . The clinical criterion define hospitalization fever one symptom suggestive influenza infection include sore throat , rhinorrhea , cough shortness breath 2 ) Desaturation &lt; 90 % room air pulse oximetry require oxygen supplement 3 ) Within 7 day onset symptom . Patients fulfil aforementioned criterion . 1 ) Age &lt; 18 year . 2 ) A know hypersensitivity celecoxib , oseltamivir zanamivir 3 ) Unable obtain informed consent 4 ) Influenza A infection diagnose beyond 7 day symptom onset 5 ) Patients receive antiviral treatment ( apart oseltamivir zanamivir ) , Nacetylcystiene , statins tradition Chinese medicine current admission 6 ) Patients renal impairment creatinine clearance &lt; 30mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>severe</keyword>
	<keyword>influenza A</keyword>
	<keyword>celecoxib</keyword>
</DOC>